Tesaro Enters Immuno-Oncology Field With AnaptysBio Deal
This article was originally published in The Pink Sheet Daily
Tesaro has plans to bring an anti-PD-1 agent into the clinic by mid-2015, with other immunotherapies to follow. The compounds will be products of AnaptysBio’s proprietary antibody platform.
You may also be interested in...
Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.
Tesaro Inc. announced the launch of a Phase III trial for its PARP inhibitor niraparib in ovarian cancer, while registrational data from three global Phase III studies for anti-emetic rolapitant are due by the end of 2013.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.